RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy
L, a lead ULSC program, following the recent Orphan Drug Designation • Recently reported Phase 1 data of Restem-L demonstrated a clinically meaningful efficacy and significant reduction in steroid use ...